512 related articles for article (PubMed ID: 18362158)
1. The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.
Rowland A; Knights KM; Mackenzie PI; Miners JO
Drug Metab Dispos; 2008 Jun; 36(6):1056-62. PubMed ID: 18362158
[TBL] [Abstract][Full Text] [Related]
2. Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation.
Rowland A; Gaganis P; Elliot DJ; Mackenzie PI; Knights KM; Miners JO
J Pharmacol Exp Ther; 2007 Apr; 321(1):137-47. PubMed ID: 17237258
[TBL] [Abstract][Full Text] [Related]
3. Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9.
Manevski N; Moreolo PS; Yli-Kauhaluoma J; Finel M
Drug Metab Dispos; 2011 Nov; 39(11):2117-29. PubMed ID: 21856742
[TBL] [Abstract][Full Text] [Related]
4. Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation.
Miners JO; Bowalgaha K; Elliot DJ; Baranczewski P; Knights KM
Drug Metab Dispos; 2011 Apr; 39(4):644-52. PubMed ID: 21245288
[TBL] [Abstract][Full Text] [Related]
5. Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes.
Mano Y; Usui T; Kamimura H
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):211-4. PubMed ID: 17697043
[TBL] [Abstract][Full Text] [Related]
6. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
[TBL] [Abstract][Full Text] [Related]
7. New Insights into SN-38 Glucuronidation: Evidence for the Important Role of UDP Glucuronosyltransferase 1A9.
Xiao L; Zhu L; Li W; Li C; Cao Y; Ge G; Sun X
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):424-428. PubMed ID: 29076612
[TBL] [Abstract][Full Text] [Related]
8. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
[TBL] [Abstract][Full Text] [Related]
9. Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
Wattanachai N; Tassaneeyakul W; Rowland A; Elliot DJ; Bowalgaha K; Knights KM; Miners JO
Drug Metab Dispos; 2012 May; 40(5):982-9. PubMed ID: 22331994
[TBL] [Abstract][Full Text] [Related]
10. Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10.
Kerdpin O; Mackenzie PI; Bowalgaha K; Finel M; Miners JO
Drug Metab Dispos; 2009 Sep; 37(9):1948-55. PubMed ID: 19487247
[TBL] [Abstract][Full Text] [Related]
11. Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine.
Shiraga T; Yajima K; Suzuki K; Suzuki K; Hashimoto T; Iwatsubo T; Miyashita A; Usui T
Drug Metab Dispos; 2012 Feb; 40(2):276-82. PubMed ID: 22031623
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A6 enzymes.
Hanioka N; Takeda Y; Jinno H; Tanaka-Kagawa T; Naito S; Koeda A; Shimizu T; Nomura M; Narimatsu S
Chem Biol Interact; 2006 Dec; 164(1-2):136-45. PubMed ID: 17027947
[TBL] [Abstract][Full Text] [Related]
13. Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7.
Tsoutsikos P; Miners JO; Stapleton A; Thomas A; Sallustio BC; Knights KM
Biochem Pharmacol; 2004 Jan; 67(1):191-9. PubMed ID: 14667942
[TBL] [Abstract][Full Text] [Related]
14. Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation.
Loureiro AI; Fernandes-Lopes C; Bonifácio MJ; Wright LC; Soares-da-Silva P
Drug Metab Dispos; 2011 Sep; 39(9):1486-94. PubMed ID: 21673130
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway.
Kerdpin O; Knights KM; Elliot DJ; Miners JO
Biochem Pharmacol; 2008 Jul; 76(2):249-57. PubMed ID: 18541222
[TBL] [Abstract][Full Text] [Related]
16. Effects of beta-estradiol and propofol on the 4-methylumbelliferone glucuronidation in recombinant human UGT isozymes 1A1, 1A8 and 1A9.
Mano Y; Usui T; Kamimura H
Biopharm Drug Dispos; 2004 Nov; 25(8):339-44. PubMed ID: 15378558
[TBL] [Abstract][Full Text] [Related]
17. Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates.
Udomuksorn W; Elliot DJ; Lewis BC; Mackenzie PI; Yoovathaworn K; Miners JO
Pharmacogenet Genomics; 2007 Dec; 17(12):1017-29. PubMed ID: 18004206
[TBL] [Abstract][Full Text] [Related]
18. Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol.
Chen M; LeDuc B; Kerr S; Howe D; Williams DA
Drug Metab Dispos; 2010 Mar; 38(3):368-75. PubMed ID: 20008037
[TBL] [Abstract][Full Text] [Related]
19. Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation.
Hanioka N; Naito T; Narimatsu S
Chemosphere; 2008 Dec; 74(1):33-6. PubMed ID: 18990428
[TBL] [Abstract][Full Text] [Related]
20. Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.
Gaganis P; Miners JO; Knights KM
Biochem Pharmacol; 2007 May; 73(10):1683-91. PubMed ID: 17343829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
